Evidence map›Paper›PMID 37114782›Full record

ArticleCombinatorial chemistry & high throughput screening2024

NPM3 as an Unfavorable Prognostic Biomarker Involved in Oncogenic Pathways of Lung Adenocarcinoma

Long Chen, Demeng Yang, Fen Huang, Weicai Xu, Xiaopan Luo, Lili Mei, Ying He

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Long ChenCenter for Rehabilitation Medicine, Department of Anesthesiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
Demeng YangFaculty of College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, Zhejiang, 315211, China.
Fen HuangDepartment of Operating Room, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
Weicai XuCenter for Rehabilitation Medicine, Department of Anesthesiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
Xiaopan LuoCenter for Rehabilitation Medicine, Department of Anesthesiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
Lili MeiMedical School, Kunming University of Science and Technology, Kunming, 6505041, China.
Ying HeCenter for Rehabilitation Medicine, Department of Anesthesiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
Hangzhou Medical College · CNZhejiang Provincial People's Hospital · CNKunming University of Science and Technology · CNNingbo University · CN

Funding

Health Bureau of Zhejiang Province 2018KY211, 2020KY418
6 · The paper itself

Abstract

backgroundThe nucleoplasmin/nucleophosmin (NPM) family was previously regarded as a critical regulator during disease development, and its mediation in carcinogenesis has achieved intensive attention recently. However, the clinical importance and functional mechanism of NPM3 in lung adenocarcinoma (LUAD) have not been reported yet.

objectiveThis study aimed to investigate the role and clinical significance of NPM3 in the development and progression of LUAD, including the underlying mechanisms.

methodsThe expression of NPM3 in pan-cancer was analyzed

resultsThe NPM3 expression was found to be markedly higher in the LUAD tumor group than the normal group and to be positively correlated with poor prognosis, tumor stages, and radiation therapy.

conclusionThe overexpression of NPM3 is an unfavorable prognostic biomarker participating in oncogenic pathways of LUAD

Indexed as

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsNucleophosminProto-Oncogene Proteins c-mycCell Line, TumorCell ProliferationHumansNuclear ProteinsPrognosisBiomarkers, TumorMYC protein, humanNuclear ProteinsNucleophosminProto-Oncogene Proteins c-myccarcinogenesis.lung adenocarcinomaMYC translational activationNPM3oncogenic pathwaysprognostic biomarker

Identifiers

PMID37114782
OpenAlexW4367320617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.